Clinical Trial Update: A Study of YM178 in Subjects With Symptoms of Overactive Bladder [Phase 3]

View source ↗

Summary

Phase 3 trial of YM178 (mirabegron) for overactive bladder has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Overactive Bladder

Drugs mentioned

• Myrbetriq (mirabegron)

Snippet

Sponsor: Astellas Pharma Inc | Conditions: Urinary Bladder, Overactive | Phase 3 | Status: COMPLETED